Skip to main content
Equibles

DIADEMA PARTNERS LP

Position in REPL — Replimune Group, Inc.

CIK 2026172 MORRISTOWN, NJ
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
-$770,049 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
7 quarters on record

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Derivatives in REPL

reported options exposure · as of Jun 30, 2026
CallValue
$7,708,041
CallShares
696,300
PutValue
$5,562,675
PutShares
502,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 139,218 $26,072,747
2 ABVX
Abivax S.A.
 163,644 $21,807,199
3 COGT
Cogent Biosciences, Inc.
 493,664 $19,104,796
4 BMRN
Biomarin Pharmaceutical Inc
 312,846 $17,901,048
5 VKTX
Viking Therapeutics, Inc.
 441,808 $17,234,930
6 EWTX
Edgewise Therapeutics, Inc.
 272,214 $11,060,054
7 KOD
Kodiak Sciences Inc.
 218,117 $8,497,838
8 IMCR
Immunocore Holdings plc
 254,863 $8,091,900

All Filings in REPL

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $5,562,675 502,500
2026-06-30 $7,708,041 696,300
2026-03-31 $3,518,235 459,900
2026-03-31 $770,049 100,660
2026-03-31 $1,572,075 205,500
2025-12-31 $2,245,290 230,997
2025-09-30 $2,565,537 612,300
2025-06-30 $301,767 32,483
2025-03-31 $726,667 74,530
2024-12-31 $1,380,540 114,000